Nordic | Biotech & Healthcare Your insights to listed Danish & Nordic biotech & healthcare stocks. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. We also present the top 3 best-performing stocks in the Nordics each week.

In the past week, Gubra and Boehringer Ingelheim signed a new partnership, Scandion Oncology identified a potentially effective treatment of gastric cancer, Biosergen’s partner submitted a clinical trial application for BSG005, and a new price target for Genmap. Further, Saniona and ViroGates carried out rights issues.

11 of the 20 listed Danish biotech companies published news. 11 of the 20 companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Cessatech continues to be the best performing stock year-to-date with a 154% increase.

---

The stocks of tomorrow! Do you want to stay tuned to the developments of impact companies and stocks in the Nordics? We have launched a blog and newsletter that dives into impact stocks listed in the Nordics. The newsletter help you to invest more sustainably in the businesses of tomorrow, track the development of multiple sectors including energy production, waste management, and carbon capture. We follow the more than100 large, medium and small cap impact companies in the Nordics.

---

Danish Company news the past week

Ascendis Pharma

FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism (Link)

Biosergen

Biosergen’s Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy (Link)

Cessatech

No news the past week

CS Medica

CS MEDICA A/S presents the CEO Letter of December 2023 (Link)

Curasight

Curasight A/S appoints CRO to run Phase 2 study with uTRACE[®] in prostate cancer (Link)

Evaxion Biotech

No news the past week

ExpreS2ion

ExpreS2ion to present new Nipah virus vaccine project in upcoming webcast (Link)

Fluoguide

No news the past week

Genmab

Genmab to Hold 2023 R&D Update and ASH Data Review Meeting (Link)

DNB raised their price target from 2,450 DKK to 2,600 DKK.

Gubra

Gubra and Boehringer Ingelheim sign 4th partnership, expanding their successful obesity treatment discovery collaboration (Link)

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

Saniona carries out a rights issue of units of approximately SEK 140 million (Link)

Saniona and Boehringer Ingelheim extend research term with up to two years (Link)

Scandion Oncology

Scandion Oncology identifies potentially effective treatment of gastric cancer (Link)

SynAct Pharma

No news the past week

ViroGates

ViroGates announces the outcome of its rights issue (Link)

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index (Link)

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a positive share price performance last week of 1.3%. The performance was driven by Scandion Oncology which rose 32% after they identified a potentially treatment of gastric cancer. Ascendis Pharma also did well with a 12% increase following acceptance from the FDA regarding the resubmitted NDA for TransCon. ViroGates and Saniona both carried out rights issues, but ViroGates ended up rising 25%, while Saniona fell 41%. The best stocks year-to-date are Curasight, Zealand Pharma, and Cessatech with 76-154% performances. However, overall the Danish biotech and healthcare stocks are in negative territory this year with a year-to-date return of -4%.

Read more about Curasight (in Danish): Positive studiedata mod lungekræft styrker Curasights stærke kursudvikling

Overview of share price developments the past week, year-to-date, and last twelve months

Nordic biotech and healthcare developments (KPHC-index)

The past week, the Kapital Partner Nordic Healthcare Index (KPHC) rose 1.9% to 62.8 and the index thus continues small improvements after hitting the all-time low in October. The Kapital Partner Nordic Healthcare Index tracks all biotech & healthcare companies in the Nordics, including large-cap companies such as Novo Nordisk and Genmab and smaller companies such as Curasight. In the past 12 months, it has significantly underperformed relative to the C25-index in Copenhagen and the S30-index in Stockholm, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC-index’s downward trajectory.

The index development for Kapital Partner Healthcare Index the past 12 months

140-89% in weekly retrun for the three best performing Nordic biotech & healthcare stocks the past week

Carbiotix AB (140%) (Nordnet) is a biotechnology company active in the microbiome area. The company currently conducts research and development and sells products and services in primarily four business areas: Diagnosis of intestinal health, prebiotic ingredients, medical food and therapeutic treatments.

Fluicell AB (98%) (Nordnet) conducts research and development in processing the composition of cells in the development of new pharmaceuticals. The company has developed a product portfolio consisting of patented research instruments, which are used to study, analyze and finally process cells. In addition, there is expertise in 2D / 3D printing.

Orphazyme A/S (89%) (Nordnet) failed biotech-projects and later sold off their assets. Today, it is a company with essentially no assets. The increase might have come following the stock being mentioned in Millionærklubben (Link in Danish)

Sources: Refinitiv & Nordnet